SpineGuard and Omnia Medical Secure U.S. Patent for DSG Technology in Sacroiliac Joint Fusion
Event summary
- SpineGuard and Omnia Medical received a U.S. patent for applying DSG technology to sacroiliac joint fusion.
- The patent covers the use of DSG tissue differentiating feedback for precise implant positioning in posterior sacroiliac fusion procedures.
- The sterile-delivered surgical kit, including Omnia’s implants and SpineGuard’s PsiFGuard guidance tool, is designed for ambulatory centers or offices.
- The sacroiliac joint fusion market was valued at over $800 million in 2021 and is projected to grow at a 16-20% CAGR through 2030.
The big picture
This patent strengthens SpineGuard and Omnia Medical's strategic collaboration, addressing a fast-growing market segment with a solution that enhances procedural safety and efficiency. The new payment code for posterior sacroiliac joint fusion surgery in the U.S., implemented in January 2024, is expected to further drive market growth.
What we're watching
- Market Expansion
- How the new patent will accelerate commercial launch and market penetration in the U.S. sacroiliac joint fusion segment.
- Revenue Impact
- Whether the application of DSG technology to sacroiliac joint fusion can significantly contribute to SpineGuard's top line and operational profitability goals.
- Competitive Dynamics
- The pace at which competitors may attempt to replicate or challenge Omnia Medical’s leadership in posterior sacroiliac fusion with enabling technology.